Effect of Omega3 in Treatment of Chronic Urticaria

Evaluation of Omega3 Function in the Treatment of Chronic Urticarial, with Clinical Evaluation and Adaptive Innate Immune Response in the double-blind Model

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110531006660N5

Enrollment

Registered

2018-01-12

Start date

2017-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic urticaria. Idiopathic urticaria

Interventions

Intervention 1: First Intervention group: Omega3 Containing 180 mg of EPA and 120 mg of DHA, one Daily for 3 Months. Intervention 2: Intervention group: This Group will Receive the Placebo-Omega-3 dr

Treatment - Drugs

Placebo

First Intervention group: Omega3 Containing 180 mg of EPA and 120 mg of DHA, one Daily for 3 Months.

Intervention group: This Group will Receive the Placebo-Omega-3 drug

Control group: Omega-3 Placebo, one Daily for 3 Months.

Eligibility

Sex/Gender

All

Age

10 Years to 40 Years

Inclusion criteria

Inclusion criteria: Chronic Idiopathic Urticaria Age between 10 and 40 Years Old Receiving Antihistamines Patient Approval Completion of Treatment for at least 30 Days

Exclusion criteria

Exclusion criteria: Concomitant illness; whether allergic or non-allergic ; Use of non-Antihistamine Medication Age Less than 10 and above 40 Acute Hives Physical Urticaria Hypersensitivity or Antihistamine Anaphylaxis Pregnant Women

Design outcomes

Primary

Measure	Time frame
Clinical resolution of urticaria. Timepoint: before and after treatment. Method of measurement: UAS7.;Thymic Stromal Lymphopoietin (TSLP). Timepoint: Before intervention and 3 months after intervention. Method of measurement: Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Enzyme-Linked Immunosorbent Assay (ELIZA).;Interferon Gama. Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.;Interleukine4 (IL4). Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.;IL35. Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.;IL32. Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.	—

Measure

Time frame

Clinical resolution of urticaria. Timepoint: before and after treatment. Method of measurement: UAS7.;Thymic Stromal Lymphopoietin (TSLP). Timepoint: Before intervention and 3 months after intervention. Method of measurement: Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Enzyme-Linked Immunosorbent Assay (ELIZA).;Interferon Gama. Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.;Interleukine4 (IL4). Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.;IL35. Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.;IL32. Timepoint: Before intervention and 3 months after intervention. Method of measurement: RT-PCR ? ELIZA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Javad Ghaffari

Sari University of Medical Sciences

ghafari@mazums.ac.ir+1 133257230

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026